Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.
Enlivex Therapeutics Ltd (ENLV) is a clinical-stage biopharmaceutical company pioneering macrophage-reprogramming therapies through its lead candidate Allocetra. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic developments across its pipeline targeting immune dysregulation.
Access primary-source ENLV news including clinical trial results, research collaborations, and regulatory filings related to Allocetra's development in sepsis, osteoarthritis, and autoimmune conditions. Our curated news collection enables efficient tracking of the company's progress in creating off-the-shelf cell therapies designed to restore immune homeostasis.
Key updates include advancements in Phase I/II trials, manufacturing partnerships, and peer-reviewed data publications. Bookmark this page for direct access to ENLV's official press releases and objective third-party analysis of their innovative approach to immune rebalancing therapies.
Enlivex Therapeutics Ltd. announced a collaboration with Mount Sinai Health System on March 1, 2021, to explore the use of Allocetra™ in combination with immune-checkpoint inhibitors for treating solid tumors. This pre-clinical program aims to investigate potential synergies between Allocetra™ and approved checkpoint inhibitors, enhancing anti-tumor responses by reprogramming macrophages. Enlivex reported positive interim results from trials involving COVID-19 and sepsis patients, indicating a promising future for Allocetra™ in immunotherapy.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the China National Intellectual Property Administration granted a notice of allowance for a new patent covering AllocetraTM, its macrophage reprogramming immunotherapy. This patent will enhance intellectual property protection in China, covering methods and uses for AllocetraTM. The product aims to reprogram macrophages to their homeostatic state, potentially addressing diseases like sepsis, COVID-19, and solid tumors. Issuance of the patent is expected in the coming months.
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced a partial exercise of its bought deal offering, resulting in the purchase of 268,205 ordinary shares at $20.00 each, generating approximately $51.3 million in gross proceeds. The funds will support clinical, regulatory, manufacturing, and R&D activities, along with potential acquisitions. The offering was conducted under an effective shelf registration statement. H.C. Wainwright & Co. served as the book-running manager. The company develops AllocetraTM, an innovative cell therapy aimed at reprogramming macrophages for better immune response.
Enlivex Therapeutics announced the issuance of U.S. Patent No. 10,927,343 for AllocetraTM, its macrophage reprogramming immunotherapy. This patent enhances intellectual property protection for treating autoimmune and inflammatory diseases, including Crohn's disease and ulcerative colitis. While focusing on critical diseases like sepsis and COVID-19, preclinical data suggest AllocetraTM may provide immune rebalancing for unmet medical needs. This development aims to establish a novel therapy mechanism targeting life-threatening conditions.
Enlivex Therapeutics (NASDAQ: ENLV) announced the closure of a public offering of 2,296,107 ordinary shares priced at $20.00 each, generating approximately $45.92 million in gross proceeds. The offering was managed by H.C. Wainwright & Co., which also received a 30-day option to purchase an additional 344,416 shares. Enlivex plans to allocate the net proceeds towards clinical, regulatory, and research activities, as well as potential acquisitions. The company operates under a shelf registration statement with the SEC.
Enlivex Therapeutics (NASDAQ: ENLV) announced an increase in its public offering to 2,296,107 ordinary shares, priced at $20.00 each, due to high demand. The offering is expected to close around February 12, 2021, pending customary closing conditions. Gross proceeds are projected to be approximately $46 million, which will be utilized for clinical, regulatory, and research activities, among other corporate purposes. H.C. Wainwright & Co. will serve as the sole book-running manager for this offering.
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced an underwriting agreement with H.C. Wainwright & Co. to issue 500,000 ordinary shares at $20.00 each, aiming for gross proceeds of $10 million. The offering is set to close around February 12, 2021, subject to customary conditions. The underwriter also has a 30-day option for an additional 75,000 shares. Proceeds will fund clinical and regulatory activities, potential acquisitions, and general corporate purposes. This offering falls under a previously filed shelf registration statement with the SEC, providing liquidity for future endeavors.
Enlivex Therapeutics announced positive results from a Phase II clinical trial of AllocetraTM in severe and critical COVID-19 patients. The trial, which treated 16 patients, showed 0% mortality at day-28 and 87.5% recovery rate. The average hospitalization duration post-treatment was 5.3 days. Based on these outcomes, the trial was concluded early to expedite regulatory submissions. Enlivex is optimistic about AllocetraTM's potential in treating severe COVID-19 and other conditions associated with dysfunctional macrophages.
Enlivex Therapeutics (Nasdaq: ENLV) announced its participation at the H.C. Wainwright BioConnect 2021 Virtual Conference, with on-demand presentations available starting January 11, 2021, at 6:00 a.m. ET. The company's lead product, AllocetraTM, is an off-the-shelf cell therapy aimed at reprogramming macrophages to their homeostatic state, targeting diseases like solid cancers and sepsis. This innovative approach aims to address significant unmet medical needs.
Enlivex Therapeutics has reported promising results from a Phase Ib trial of AllocetraTM for severe sepsis. Comparing 10 treated patients to 37 matched controls revealed significant benefits: zero mortality in the treated group versus 27% in controls, a 58% reduction in ICU stay (4.7 vs. 11.1 days), and no increase in organ-failure among treated patients. The trial confirms AllocetraTM as a safe and potentially effective treatment option for sepsis, a condition currently lacking effective therapies. Full data is available on medRxiv.org.
